Hair Care

• Finast is used for treating and enlarged prostate, and it is also used by men wishing to treat male pattern baldness. This medicine can shrink the prostate in men affected by benign prostate hyperplasia (BPH), which is important, as an enlarged prostate can put the urethra and bladder under pressure, leading to urination problems.

• Finax tablets 1mg are used to treat hair loss in men with male pattern baldness (androgenic alopecia), to increase hair growth and prevent further hair loss from all areas of the scalp, including the front. Androgenic alopecia is an inherited condition that accounts for 99% of hair loss in men. Finax tablets 1mg can help reverse balding in men with mild to moderate hair loss but does not restore hair that has been lost for a long time. It is not used to treat hair loss in women.

• Fincar an active ingredient which is used to treat men for hair loss, and to relieve symptoms of BPH (benign prostatic hyperplasia, a condition in which the prostate becomes enlarged, resulting in urination problems).

• Finpecia is a synthetic antiandrogen that acts by inhibiting type II 5-alpha reductase, the enzyme that converts to dihydrotestosterone (DHT). It is used as a treatment in benign prostatic hyperplasia (BPH) in low doses, and prostate cancer in higher doses. A May, 2008 study indicates that Finpecia reduces the rate of prostate cancer by 30%. It is also indicated for use in combination with therapy to reduce the risk for symptomatic progression of BPH. In addition, it is registered in many countries for androgenetic alopecia (male-pattern baldness).
• Finpecia was approved initially in 1992 as Proscar, a treatment for enlarged prostate, but the sponsor had studied 1 mg of Finpecia and demonstrated hair growth in male pattern hair loss. Merck sells it under the brand name Propecia.Health organisations and practising clinicians have expressed concerns that Propecia gives rise to persistent side-effects in some men.

Proscalpin is categorized as a type II reductase inhibitor. This means that this drug inhibits the functioning of 5-alpha reductase. This is an enzyme that is necessary for to be transformed into  in the scalp, which is a hormone variation that has been identified as responsible for follicle death and the loss of hair. Through the inhibition of the conversion process, Proscalpin lowers the levels of DHT and slows down the hair loss process.

Generic Rogaine in the form of Tugain Foam 5% is used to treat androgenic alopecia only in men.
Tugain is a topical treatment for androgenic alopecia or male pattern baldness. Tugain is used in men to stabilise hair loss and induce re-growth of hair in areas where the hair is thinning, but should not be used for frontal baldness or receding hairline. Tugain is most effective where hair loss has just started or is recent and there are smaller areas of hair loss of the vertex.  

Mintop Foam which is known to interact with other drugs like (HCl). These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

MECHANISM OF ACTION: Mintop Foam is thought to promote the survival of human dermal papillary cells or hair cells by activating both extracellular signal-regulated kinase and Akt and by preventing cell death by increasing the ratio of BCl-2/Bax. Mintop Foam may stimulate the growth of human hairs by prolonging anagen through these proliferative and anti-apoptotic effects. Mintop Foam, when used as a vasodilator, acts by opening triphosphate-sensitive potassium channels in vascular smooth muscle cells.

• Finpecia is a synthetic antiandrogen that acts by inhibiting type II 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). It is used as a treatment in benign prostatic hyperplasia (BPH) in low doses, and prostate cancer in higher doses. A May, 2008 study indicates that Finpecia reduces the rate of prostate cancer by 30%. It is also indicated for use in combination with doxazosin therapy to reduce the risk for symptomatic progression of BPH. In addition, it is registered in many countries for androgenetic alopecia.